AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02312804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily on each day of the 21 day cycle.
Study NCT02312804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
Study NCT02312804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
Study NCT01050114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: onaBoNT-A
Description: onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder.
Study NCT01050114 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxybutynin ER
Description: Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
Study NCT04223245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise+multi-modal sensory feedback (MMSF)
Description: home program of 3 stepping exercises and 3 balance exercises with progression of speed, step distance and reduced vision. Real-time sensory feedback during ex. using ankle, wrist wts., laser on chest and mat with footpads and clickers (auditory feedback during stepping)
Study NCT04773886 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Biodentine
Description: Vital Pulpotomy will be done using Biodentine as pulp capping agent
Study NCT04773886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: Vital Pulpotomy will be done using Biodentine as pulp capping agent
Study NCT04773886 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich fibrin
Description: 10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.~The product obtained after centrifugation consisted of three layers:~* Acellular platelet plasma- top most layer~* Platelet rich fibrin -middle layer~* Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece
Study NCT02351596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy Core Stability Group Programme
Description: The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this.
Study NCT04223245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: 3 stepping and 3 balance exercises which are to progress in speed and distance of movement as well as progress to eyes closed while performing.
Study NCT02351596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
Study NCT03743831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: orotracheal intubation by direct laryngoscopy
Description: Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
Study NCT03743831 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: orotracheal intubation by indirect laryngoscopy
Description: orotracheal intubation by indirect laryngoscopy by Airtraq
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (CP)
Description: Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 45 mg (CP)
Description: Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 90 mg (CP)
Description: Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 45 mg (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
Study NCT00723528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab 90 mg (After CP)
Description: After the controlled period (i.e., during the active drug treatment period \[Weeks 12-64\]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
Study NCT00874887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 0.5% HCI ophthalmic solution
Description: 1 drop in study eye three times a day for 14 days
Study NCT00874887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gatifloxacin ophthalmic solution 0.3%
Description: 1 drop in study eye four times a day for 14 days
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SCA3/MJD molecular diagnosis
Description: Double-blind molecular diagnosis for determination of the presence of the mutation.
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Cross-sectional Cognitive evaluation with~* CCAS Scale~* Trail-Making Test parts A and B~* Stroop Color-Word Test
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric Evaluation
Description: Cross-sectional Psychiatric evaluation with Hamilton-Anxiety and Hamilton-Depression rating scales.
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Neurological Evaluation
Description: Cross-sectional neurological evaluation with standardized clinical scales - SARA, SCAFI and CCFS.
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Emotional Attribution Evaluation
Description: Cross-sectional emotional attribution evaluation by means of the Reading the Mind in the Eyes Test (RMET).
Study NCT04714307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Activities of Daily Living
Description: Cross-sectional evaluation of Activities of Daily Living (ADLs) by means of Friedreich Ataxia Rating Scale Part II.
Study NCT01523626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Total body Computed Tomography.
Description: The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT.
Study NCT01523626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional imaging and selective CT scanning.
Description: The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers.
Study NCT00338481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine p.o.
Description: Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c.
Study NCT00338481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine s.c.
Description: False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg
Study NCT02264106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban tablet
Study NCT02264106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban tablet
Study NCT02264106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban double chamber sachet
Study NCT02264106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban double chamber sachet
Study NCT02264106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study NCT01087476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Description: Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
Study NCT00384852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM
Study NCT00384852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2/CPM
Study NCT00384852 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rhBMP-2/CPM
Study NCT02620670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity of moderate intensity for 3 days
Description: The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
Study NCT05240222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-implementation enhancement strategies (SC-PIES)
Description: The SC-PIES was delivered to teachers as a one-hour professional development session immediately before receiving specific training about evidence-based student behavioral management practices and follow-up consultation. SC-PIES content was grounded in three social-cognitive principles: (a) growth mindset, (b) saying-is-believing, and (c) commitment and consistency.
Study NCT05240222 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Participants in the active control condition will meet with school administrators to talk about their work irrelevant to SC-PIES or student behaviors. The meeting lasted for the same duration as the SC-PIES at the same time as those in the treatment condition.
Study NCT00283699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: Active drug or placebo dosed bid p o for 8days
Study NCT00283699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT01993030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HQ® Matrix Medical Wound Dressing
Study NCT01993030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sidaiyi® wound dressing
Study NCT04503993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
Description: The hepatitis B tests are released into the electronic medical charts of at-risk patients who have never been screened for chronic hepatitis B using population health tools.
Study NCT04277026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Walking
Description: Eight weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
Study NCT03334825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced housing placement assistance
Description: assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
Study NCT03334825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard housing placement assistance
Description: standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
Study NCT03136380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756H
Description: Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
Study NCT03136380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
Study NCT02134080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04457845
Description: PF-04457845 will be administered orally at 4mg daily for four weeks.
Study NCT00589641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RP (relapse prevention) + Enhanced TAU
Description: CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
Study NCT02134080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally at 4mg daily for four weeks.
Study NCT03245086 — intervention group
Intervention type: DEVICE
Intervention: Transanal hemorrhoid dearterialization
Description: The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
Study NCT03245086 — intervention group
Intervention type: PROCEDURE
Intervention: Ferguson hemorrhoidectomy
Description: The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
Study NCT02031965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic HSV-1716
Description: Given IT
Study NCT02031965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT02031965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT02031965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01012674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Study NCT00589641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced TAU Alone
Description: Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
Study NCT04313556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lateral patellar release
Description: Arthroscopic lateral patellar reticular release
Study NCT00975247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receiving an educational booklet
Description: Patients who receive an educational booklet will be considered to be receiving an intervention
Study NCT00688909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg daily by mouth for 6 months
Study NCT02926326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCT197
Description: A single dose of BCT197
Study NCT02926326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin
Description: 3 daily doses of Azithromycin
Study NCT00445302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
Study NCT00445302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plerixafor
Description: Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
Study NCT04224935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte Platelet rich fibrin membrane
Description: the use of Leukocyte Platelet rich fibrin as grafting materials for treatment of recession
Study NCT02668614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WR-22 model microwave sensor
Study NCT03530384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
Study NCT03530384 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control training
Description: Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
Study NCT02066792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: D-cycloserine is a medication thought to be associated with fear extinction.
Study NCT02066792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: D-cycloserine is a medication thought to be associated with fear extinction.
Study NCT02066792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT02066792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT02066792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill
Study NCT02066792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.